Insider trade

Officer sold ~$87K of GILD shares in the open market

Traded Sep 15, 2026 · Filed Sep 16, 2026

~$87K
Reported value · 600 sh @ $145.29: 117K
Holds after · shares reported: +0.8%
stock since the trade · S&P 500 +0.9%, $146.30 → $147.50 on Oct 1

Why it stands out

Gilead Sciences's Chief Comm & Corp Aff Officer sold $87K of Gilead Sciences shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 15, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 16, 2026

Officer$25K–$100KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$87,174

Shares × reported transaction price

Timing vs results

42 days after results of Aug 4, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $146.30 on Sep 15, 2026, 32% above its 52-week low and 6% below its high, after a 12% rise over the previous 30 trading days

52-week range $110.56 (Oct 2, 2025) to $155.80 (Feb 11, 2026), 79% of the way up, from 251 adjusted closes. 30 trading days earlier: $131.15 on Aug 3, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Bixlenvo Sunlenca Starter Pack (Copackaged) on Aug 27, 2026, 19 days before this trade.

New drug application approved. Active ingredient: Bictegravir Sodium, Lenacapavir Sodium, Lenacapavir Sodium. From openFDA. Dates only; no link between the two is implied